Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005. The ANNX stock yearly return is shown above.
The yearly return on the ANNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|